New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

Newsom backtracks on return to office order for California workers amid union demands ...

Amgen said on Monday its experimental therapy helped patients with advanced gastric cancer live longer when combined with ...

Amgen Inc. (NASDAQ:AMGN) ranks among the best set-it-and-forget-it stocks to buy. On June 24, Piper Sandler reaffirmed its ...

In the last year, many Amgen Inc. (NASDAQ:AMGN) insiders sold a substantial stake in the company which may have sparked ...

Amgen said on Monday its experimental cancer therapy significantly improved overall survival in patients with advanced ...

Indian biosimilars developer Biocon Biologics, a subsidiary of Biocon Ltd has announced that the European Commission (EC) has ...

In a detail-thin announcement, Amgen said that adding bemarituzumab to chemotherapy improved overall survival, though ...

Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...

Amgen & Zai Lab's trial shows bemarituzumab + chemo boosts survival in gastric cancer with FGFR2b. Read more here.

Amgen’s investigational monoclonal antibody paired with chemotherapy significantly improved overall survival for patients in ...